<DOC>
	<DOCNO>NCT01492582</DOCNO>
	<brief_summary>This trial comprehensively evaluate human papillomavirus ( HPV ) vaccine cancer survivor 9 26 year age ( 1 ) determine prevalence HPV vaccine initiation among young cancer survivor , ( 2 ) determine immune response safety/tolerability quadrivalent nonavalent HPV vaccine young cancer survivor .</brief_summary>
	<brief_title>Vaccine Therapy Preventing Human Papillomavirus Infection Younger Cancer Survivors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Using cross-sectional survey approach , estimate prevalence HPV vaccine non-initiation : ) Examine sociodemographic , behavioral , medical determinant HPV vaccine non-initiation . II . Using single-arm , phase II , open-label , prospective longitudinal trial design , evaluate 3-dose HPV quadrivalent ( HPV4 ) nonavalent ( HPV9 ) vaccine series measure follow endpoint : ) Determine immunogenicity follow third final vaccine dose ; b ) Identify clinical/host factor influence immunogenicity ; c ) Determine safety/tolerability HPV vaccine cancer survivor . III . Evaluate persistence antibody response 2 year post vaccine initiation identify clinical/host factor influence response persistence . OUTLINE : AIM 1 ( SURVEY ) : Patients ( age 18-26 year ) parent ( patient age 9-17 year ) complete survey regard patient 's HPV vaccination status , knowledge HPV-related disease , factor important make decision regard vaccination . AIM 2 ( VACCINE EVALUATION ) : Patients previously immunize HPV receive quadrivalent human papillomavirus recombinant vaccine ( HPV-6 , -11 , -16 , -18 , patient enrol 3/1/16 ) nonavalent human papillomavirus recombinant vaccine ( HPV-6 , -11 , -16 , -18 , -31 , -33 , -45 , -52 , -58 , patient enrol 3/1/16 ) intramuscularly day 1 , 8-12 week , 24-32 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>AIM 1 ( SURVEY ) ( AIM 1 closed enrollment ) Cancer survivor Between 12 60 month completion cancer therapy ( chemotherapy , radiation , hematopoietic cell transplant [ HCT ] ) Scheduled return clinic visit one participating institution English Spanishspeaking Willing provide inform consent/assent study participation AIM 2 ( VACCINE EVALUATION ) Meets inclusion criterion outline Aim 1 Survey response indicate prior history HPV vaccination OR patient prior history HPV vaccination self parent/caregiverreport English Spanishspeaking Medical clearance treat clinician study participation Agrees return participate institution 3 HPV vaccine injection Willing provide inform consent/assent study participation AIM 2 ( VACCINE EVALUATION ) Allergy component HPV vaccine include yeast aluminum Thrombocytopenia ( platelet count &lt; 50K ) coagulation disorder would contraindicate intramuscular injection Transfusion blood product intravenous immune globulin within 3 month study entry Female , ) currently pregnant lactating , b ) childbearing potential unwilling avoid pregnancy vaccine phase study ( begin Day 1 continue least 4 week 3 vaccine dos administer )</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>